Evidence map›Paper›PMID 35865902›Full record

ArticleChemical science2022

Visualizing the mode of action and supramolecular assembly of teixobactin analogues in

Michael A Morris, Alexander Vallmitjana, Fabian Grein, Tanja Schneider, Melina Arts, Chelsea R Jones, Betty T Nguyen, Mohammad H Hashemian, Melody Malek, Enrico Gratton and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Case Study: Illuminating the Nanoscale World of Microbiology.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  3. Drug repurposing of natural depsipeptide fromFrontiers in pharmacology · 2025
    Article
  4. Article
  5. Sensing of Antibiotic-Bacteria Interactions.Antibiotics (Basel, Switzerland) · 2023
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Michael A MorrisDepartment of Chemistry, University of California, Irvine Irvine California 92697 USA jsnowick@uci.edu.ORCID https://orcid.org/0000-0003-4526-271X
Alexander VallmitjanaLaboratory for Fluorescence Dynamics, Department of Biomedical Engineering, University of California, Irvine Irvine California 92697 USA.ORCID https://orcid.org/0000-0002-7149-9385
Fabian GreinInstitute for Pharmaceutical Microbiology, University of Bonn, University Hospital Bonn Bonn 53115 Germany.ORCID https://orcid.org/0000-0001-8394-8961
Tanja SchneiderInstitute for Pharmaceutical Microbiology, University of Bonn, University Hospital Bonn Bonn 53115 Germany.ORCID https://orcid.org/0000-0001-7269-4716
Melina ArtsInstitute for Pharmaceutical Microbiology, University of Bonn, University Hospital Bonn Bonn 53115 Germany.ORCID https://orcid.org/0000-0003-0344-6107
Chelsea R JonesDepartment of Chemistry, University of California, Irvine Irvine California 92697 USA jsnowick@uci.edu.ORCID https://orcid.org/0000-0002-8347-6885
Betty T NguyenDepartment of Chemistry, University of California, Irvine Irvine California 92697 USA jsnowick@uci.edu.
Mohammad H HashemianDepartment of Chemistry, University of California, Irvine Irvine California 92697 USA jsnowick@uci.edu.
Melody MalekDepartment of Chemistry, University of California, Irvine Irvine California 92697 USA jsnowick@uci.edu.ORCID https://orcid.org/0000-0002-1083-0791
Enrico GrattonLaboratory for Fluorescence Dynamics, Department of Biomedical Engineering, University of California, Irvine Irvine California 92697 USA.ORCID https://orcid.org/0000-0002-6450-7391
James S NowickDepartment of Chemistry, University of California, Irvine Irvine California 92697 USA jsnowick@uci.edu.ORCID https://orcid.org/0000-0002-2273-1029
University of California, Irvine · USUniversity of Bonn · DEFluor (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Teixobactin has been the source of intensive study and interest as a promising antibiotic, because of its excellent activity against drug-resistant Gram-positive pathogens and its novel but not yet fully understood mechanism of action that precludes drug resistance. Recent studies have demonstrated that the mode of action of teixobactin is more complicated than initially thought, with supramolecular assembly of the antibiotic appearing to play a critical role in the binding process. Further studies of the interactions of teixobactin with bacteria and its molecular targets offer the promise of providing deeper insights into its novel mechanism of action and guiding the design of additional drug candidates and analogues. The current study reports the preparation and study of teixobactin analogues bearing a variety of fluorophores. Structured illumination microscopy of the fluorescent teixobactin analogues with

Identifiers

PMID35865902
PMCPMC9258396
OpenAlexW4285303330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.